Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Voxelotor open-label extension in sickle cell disease
NCT04188509Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Nov 2019
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 3 trial of voxelotor in sickle cell disease (SCD), sponsored by Pfizer. Started Nov 2019; status: terminated.
02
Drugs
voxelotor
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT04188509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04188509.